SCHEMBL25440357

SCHEMBL25440357

CC1NC(c2ccc(F)cc2)=CO1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ GRM2 Q14416 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ TSHR P16473 2/20 0.32
▸ PTGS1 P23219 2/20 0.32
▸ PTGS2 P35354 2/20 0.32
▸ TP53 P04637 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ POLB P06746 2/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ PGR P06401 1/20 0.31
▸ LPL P06858 1/20 0.31
▸ LIPG Q9Y5X9 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ GAA P10253 1/20 0.30
▸ NOTUM Q6P988 1/20 0.30
▸ ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10337645 0.59 BCL2L1 (0.55) NPC1RAB9ASMN1; SMN2POLBLPL
SCHEMBL12562793 0.59 BCL2L1 (0.55) NPC1RAB9ASMN1; SMN2POLBLPL
SCHEMBL26821699 0.59 BCL2L1 (0.55) NPC1RAB9ASMN1; SMN2POLBLPL
SCHEMBL197346 0.59 BCL2L1 (0.55) NPC1RAB9ASMN1; SMN2POLBLPL
SCHEMBL10300262 0.59 BCL2L1 (0.55) NPC1RAB9ASMN1; SMN2POLBLPL
SCHEMBL9812881 0.57 NPC1 (0.44) NPC1RAB9ASMN1; SMN2TSHRPTGS1
SCHEMBL28060792 0.57 BCL2L1 (0.52) NPC1RAB9ASMN1; SMN2POLBLPL
SCHEMBL2289115 0.54 NPC1 (1.00) NPC1RAB9ASMN1; SMN2TSHRTP53
SCHEMBL20804472 0.54 ACHE (0.81) NPC1RAB9ASMN1; SMN2PTGS1LMNA
Methylamine SCHEMBL27499302 0.53 ACHE (0.60) ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3555100-B1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT AGENEBIO INC (US) 2023-05-10 — — EP disclosed
Send feedback